Clinical trials: Interstitial Cystitis and Bladder Pain Syndrome
- Condition Interstitial Cystitis and Bladder Pain Syndrome
- Funder type Industry (pharma, biotech, devices)
Cystitis, Interstitial, Painful Bladder Syndrome
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome
This is a safety and efficacy study of LiRIS® in females with interstitial cystitis/bladder pain syndrome.
- Trial name
- NCT02411110
- Testing
- LiRIS®
- Where
- 34 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- Allergan
Interstitial Cystitis, Painful Bladder Syndrome
An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis
The purpose of this study is to determine whether PD 0299685 is effective in the treatment of symptoms associated with interstitial cystitis/painful bladder syndrome, such as pain, urinary urgency and frequency.
- Trial name
- NCT00739739
- Testing
- PD 0299685 at 15mg BID, PD 0299685 at 30mg BID
- Where
- 44 sites in United States, Canada and 4 more
- Volunteers
- 161 people
- Sponsor
- Pfizer
Interstitial Cystitis
Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome
The purpose of this study is to assess the safety and tolerability of two doses of LP08 compared to placebo. Hypothesis: Safety of the LP-08 therapy will not be significantly different from the placebo group.
- Trial name
- NCT01393223
- Testing
- LP-08 80mg, Normal saline, LP-08 20mg
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Lipella Pharmaceuticals, Inc.
Interstitial Cystitis, Bladder Pain Syndrome
A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
The aim of this study is to assess whether IW-3300 is safe and works for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS).
- Trial name
- NCT05740007
- Testing
- IW-3300 rectal foam
- Where
- 53 sites in United States
- Volunteers
- 98 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Interstitial Cystitis, IC
Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients
The investigators believe that this study is of importance of several aspects: 1. It evaluates a new mode of bladder instillation that may bypass the drawbacks of the current instillation mode. 2.
- Trial name
- NCT01997983
- Testing
- TC-3 Gel mixed with Botox (BTX)
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- UroGen Pharma Ltd.
Cystitis, Interstitial, Urinary Bladder Disease
A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)
In this study several dose levels of ASP3652, given orally for 12 weeks, will be compared with placebo in the treatment of female patients with Bladder Pain Syndrome / Interstitial Cystitis.
- Conditions
- Cystitis, Interstitial, Urinary Bladder Disease, Pain, Urologic Diseases
- Trial name
- AMARANTH (NCT01613586)
- Testing
- ASP3652
- Where
- 60 sites in Belgium, Czechia and 10 more
- Volunteers
- 287 people
- Sponsor
- Astellas Pharma Europe B.V.
Interstitial Cystitis, Bladder Pain Syndrome
Assessment of Urinary Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) Technology in the Evaluation and Management of Females With Chronic Bladder Pain and Cystitis-like Symptoms
Real-world clinical practice multicenter study to determine the clinical implications of employing PCR/NGS technology to identify and treat potential urinary pathogens in female participants identified with bladder pain and/or…
- Trial name
- NCT05276466
- Testing
- Polymerase Chain Reaction and Next-Generation DNA Sequencing
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- MicroGenDX
Interstitial Cystitis, Bladder Pain Syndrome
PK and Safety of SI-722 in IC/BPS
This study is designed randomized, double-blind, placebo-controlled trial in Interstitial Cystitis/Bladder Pain Syndrome patients.
- Trial name
- NCT04208087
- Testing
- SI-722
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- Seikagaku Corporation
Cystitis, Interstitial
A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome
In a previous study in patients with interstitial cystitis/ painful bladder syndrome (IC/PBS), tanezumab has shown to be efficacious in relieving the pain associated with IC/PBS, as well as some effect on reducing urinary…
- Trial name
- NCT00999518
- Testing
- Tanezumab
- Where
- 171 sites in United States, Belgium and 12 more
- Volunteers
- 205 people
- Sponsor
- Pfizer
Interstitial Cystitis and Bladder Pain Syndrome
Real-world Evidence Study on Cystistat
This study will be conducted with the aim of ensuring the continued acceptability of the benefit-risk ratio and confirming the safety and performance of the device throughout its expected lifetime.
- Trial name
- IC/BPS (NCT05544695)
- Testing
- intravesical sodium hyaluronate (Cystistat®)
- Where
- Austria
- Volunteers
- 74 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Interstitial Cystitis, Painful Bladder Syndrome
Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome
A new device for interstitial cystitis is compared to inactive control to determine if it is safe and effective. The study lasts approximately 7 weeks with a 19-week follow-up period.
- Trial name
- NCT00919113
- Testing
- 2% sodium chondroitin sulfate
- Where
- 20 sites in United States
- Volunteers
- 98 people
- Sponsor
- Watson Pharmaceuticals
Bladder Pain Syndrome, Interstitial Cystitis
A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis
The purpose of this study is to investigate efficacy, safety and tolerability of ASP6294 in female participants with Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC).
- Trial name
- SERENITY (NCT03282318)
- Testing
- ASP6294
- Where
- 28 sites in Belgium, Czechia and 8 more
- Volunteers
- 119 people
- Sponsor
- Astellas Pharma Europe B.V.
Bladder Pain Syndrome
The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005)
The purpose of this study is to assess the efficacy of gefapixant (AF-219/MK-7264) in female participants with moderate to severe pain associated with interstitial cystitis/bladder pain syndrome (IC/BPS) after 4 weeks of…
- Trial name
- NCT01569438
- Testing
- Gefapixant
- Where
- 41 sites in United States
- Volunteers
- 107 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Interstitial Cystitis
Safety Study of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome
The purpose of this study is to determine the safety and pharmacokinetics of TTI-1612 in women with interstitial cystitis/bladder pain syndrome.
- Trial name
- NCT01559961
- Testing
- TTI-1612
- Where
- 4 sites in Canada
- Volunteers
- 28 people
- Sponsor
- Trillium Therapeutics Inc.
Interstitial Cystitis, Bladder Pain Syndrome
Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
The purpose of this study is to determine if the combination product (URG101) is safe and effective versus its individual components (Heparin Sodium and Lidocaine Hydrochloride) for the treatment of Interstitial Cystitis/Bladder…
- Trial name
- NCT02591199
- Testing
- URG101, Lidocaine, Heparin
- Where
- 11 sites in United States
- Volunteers
- 91 people
- Sponsor
- Urigen
Interstitial Cystitis/Bladder Pain Syndrome
Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with interstitial cystitis/bladder pain syndrome, compared to placebo.
- Trial name
- NCT06285214
- Testing
- V117957
- Where
- 24 sites in United States
- Volunteers
- 47 people
- Sponsor
- Imbrium Therapeutics
Interstitial Cystitis, Bladder Pain Syndrome
Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome
This study evaluates the effects of two doses of oral AQX-1125 on bladder pain and other urinary symptoms in subjects with interstitial cystitis/bladder pain syndrome.
- Conditions
- Interstitial Cystitis, Bladder Pain Syndrome, Painful Bladder Syndrome, Chronic Interstitial Cystitis
- Trial name
- LEADERSHIP 301 (NCT02858453)
- Testing
- AQX-1125 100 mg, AQX-1125 200 mg
- Where
- 120 sites in United States, Belgium and 10 more
- Volunteers
- 433 people
- Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
Interstitial Cystitis, Bladder Pain Syndrome
Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)
This is an open-label study that will enroll participants with Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS). The study will assess PRN (as needed) dosing of up to 6 intravesical (via catheter) doses of VNX001 (study…
- Trial name
- NCT06394830
- Testing
- VNX001
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Vaneltix Pharma, Inc.
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a chronic and debilitating urological complex of disorders characterized by symptoms of bladder pain or discomfort, mostly upon bladder filling, and often accompanied by…
- Trial name
- IC/BPS POC (NCT05141006)
- Testing
- BOTOX
- Where
- 43 sites in United States, Canada
- Volunteers
- 83 people
- Sponsor
- AbbVie
Interstitial Cystitis, Bladder Pain Syndrome
Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS
This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, multi-center, single-dose, pharmacodynamic study designed to evaluate the efficacy and safety of the combination product (VNX001) versus placebo and…
- Trial name
- NCT05737121
- Testing
- VNX001, Lidocaine, Heparin
- Where
- 14 sites in United States
- Volunteers
- 120 people
- Sponsor
- Vaneltix Pharma, Inc.